Inside Toronto’s First Documented HIV Remission Case
Clinicians in Toronto have reported the first documented HIV remission case in the country, involving a 62-year-old man living with HIV since 1999. After more than two decades on antiretroviral therapy (ART), he developed acute myelogenous leukemia in 2021 and underwent a bone marrow transplant at Princess Margaret Cancer Centre. The donor’s stem cells carried a rare delta-32 mutation in the CCR5 gene, which prevents production of a key receptor HIV uses to enter immune cells. Following successful cancer treatment and transplant, the patient stopped ART in July 2025. As of April 2026, HIV remains undetectable in his blood, and he is described as being in sustained HIV remission and a possible cure. The case, presented at the Canadian Association of HIV Research Conference, has quickly become known as the “Toronto patient” and is drawing global attention to this proof-of-concept approach.
Collaboration Behind the ‘Toronto Patient’ Breakthrough
This HIV remission case is the result of a tightly coordinated effort across several leading institutions. The work was co-led by Dr. Mario Ostrowski, a clinician-scientist at Unity Health Toronto’s St. Michael’s Hospital and professor at the University of Toronto’s Temerty Faculty of Medicine, and Dr. Sharon Walmsley, director of the HIV clinic at University Health Network (UHN) and also a Temerty Medicine professor. Their teams connected oncology, immunology, and infectious disease expertise to select a CCR5 delta-32 donor and design a careful treatment and monitoring plan. UHN’s Princess Margaret Cancer Centre provided the highly specialized bone marrow transplant, while Unity Health and UHN HIV programs contributed long-term virologic follow-up. This kind of cross-hospital, cross-discipline collaboration is increasingly essential in HIV treatment advances, especially when interventions—for now—are reserved for people who already need intensive procedures such as transplants for blood cancers.
Remission vs. Cure: How Do Experts Draw the Line?
Terms like “HIV remission case” and “bone marrow transplant cure” can sound interchangeable, but clinicians use them differently. Remission means that HIV is undetectable in blood and key tissues without ongoing ART, often for months or years, using ultrasensitive tests. The virus may still exist in hidden reservoirs, so regular monitoring is essential. A cure, by contrast, implies the virus cannot rebound even after long-term observation and after the immune system has been challenged. Because HIV can hide in very small numbers of cells, proving a complete cure is extremely difficult. That is why the Toronto team describes this as sustained remission and a possible cure rather than a definitive one. Over the coming years, researchers will track viral load, immune responses, and any signs of viral reactivation to determine whether this case ultimately qualifies as a functional HIV cure or remains an extraordinary, but still provisional, remission.
How the ‘Toronto Patient’ Compares to Earlier Bone Marrow Cases
The Toronto HIV research milestone fits into a small but growing group of bone marrow transplant cure narratives, such as the widely known Berlin and London patients. In each, individuals had HIV and a life-threatening blood cancer requiring a transplant. Clinicians identified donors with the CCR5 delta-32 mutation so that the new immune system would be resistant to HIV. The Toronto case closely follows this playbook: long-standing HIV infection controlled by ART, development of leukemia, then a CCR5 delta-32 transplant and, later, structured ART interruption with continued viral suppression. While technical details and monitoring strategies differ among cases, the underlying concept is similar—replace vulnerable immune cells with HIV-resistant ones and eliminate most infected cells during cancer treatment. These cases collectively strengthen evidence that a functional HIV cure is biologically achievable, even though the approach is too risky and complex to use broadly in people who do not already need a transplant.
Why Bone Marrow Transplants Won’t Be the Everyday Cure—and What Comes Next
Bone marrow transplant–driven remission is a powerful proof of concept but not a scalable solution. Transplants carry significant risks and are typically reserved for life-threatening cancers, not for otherwise stable people on ART. Suitable CCR5 delta-32 donors are rare—only about one percent of people of European ethnicity have such bone marrows—making this approach impractical as a population-wide HIV cure strategy. Its main value is scientific: it shows that targeting viral reservoirs and blocking CCR5 can, in some cases, lead to functional HIV cure. Looking ahead, researchers are applying lessons from these cases to gene-editing strategies, engineered immune cells, and antibody-based therapies. AI and advanced data platforms are also reshaping the landscape, helping sponsors optimize trial protocols, predict enrollment feasibility, and engineer better biologics. For everyday patients, ART will remain the backbone of care, but the next decade is likely to bring more targeted, long-acting treatments and carefully designed cure-focused trials.
